

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): **June 24, 2021**

Assure Holdings Corp.

(Exact name of registrant as specified in its charter)

Nevada	333-251829	82-2726719
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4600 South Ulster Street, Suite 1225 Denver, CO		80237
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: **720-287-3093**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: **None**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD

On June 24, 2021, Assure Holdings Corp. issued a press release announcing that it supported a successful auditory brainstem implant surgery. A copy of the press release is attached to this report as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended. The information set forth in Item 7.01 of this report shall not be deemed an admission as to the materiality of any information in this report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01 Exhibits

Exhibit No.	Name
99.1	Press Release dated June 24, 2021
104	Cover Page Interactive Data File (formatted in Inline XBRL and included as Exhibit 101).



Assure Holdings Supports Rare Auditory Brainstem Implant Surgery

DENVER, June 24, 2021 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the **Company**” or **“Assure”**) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (**“IONM”**), is pleased to announce that it supported a successful auditory brainstem implant surgery.

The procedure was performed by Moises Arriaga, MD, a Louisiana based neurotologist, and Assure neurophysiologists utilizing intraoperative neuromonitoring equipment from Cadwell Industries, Inc. (**“Cadwell”**), a provider of neurodiagnostic solutions.

The auditory brainstem implant surgery was performed to restore hearing in a patient who had lost this function. The procedure is rare and required a tightly integrated surgical team, including an Assure neurophysiologist using Cadwell Cascade Surgical Studio, to support Dr. Arriaga as he identified and mapped the lateral recess of the fourth ventricle, confirming the cochlear nucleus to pinpoint the optimal placement for the implanted stimulating device. In addition, neurophysiologists monitored all associated lower cranial nerves, minimizing the potential negative side effects of the implant.

“Assure Neuromonitoring was a critical part of the team allowing us to successfully complete the auditory brainstem implant procedure,” said Dr. Moises Arriaga. “Their attention to detail and pre-emptive troubleshooting allowed us to complete this important procedure and restore hearing for this patient who would otherwise have no sound input whatsoever.”

“This is a very challenging procedure due to implant shifting, the potential for improper mapping and targeting as well as negative side effects associated with stimulating the implant, which is why I am extremely proud to report that the activation led by Dr. Arriaga was highly successful,” said Stephanie Krouse, VP, National Technologist Manager at Assure. “Assure is proud to push the boundaries of innovation and help progress patient care to a new standard.”

“Cadwell is privileged to play a role in the research and treatment of profound hearing loss utilizing Auditory Brainstem Implants,” said Julia Caviness, IONM product manager at Cadwell. “Integrating Cascade Surgical Studio and IOMAX intraoperative monitoring solutions with the implanted devices for brainstem auditory evoked response testing is a vital part of this multifaceted procedure. This adds another dimension to our goal of improving patient outcomes around the world.”

About Assure Holdings

Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Assure Neuromonitoring is recognized as providing the highest level of patient care in the industry and has earned the Joint Commission’s Gold Seal of Approval®. For more information, visit the Company’s website at www.assureneuromonitoring.com.



4600 S. Ulster Street
Suite 1225
Denver, CO 80237
(720)287-3093

About Cadwell

Cadwell Industries, Inc. is a global leading provider of neurodiagnostic and neuromonitoring solutions. Our mission is to help patients around the world live better and longer lives. Learn more at www.cadwell.com.

Forward-Looking Statements

This news release may contain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to: the Company pushing the boundaries of innovation and helping to progress patient care to a new standard. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company may not be successful in pushing the boundaries of innovation and helping to progress patient care to a new standard; the uncertainty surrounding the spread of COVID-19 and the impact it will have on the Company's operations and economic activity in general and the risks and uncertainties discussed in our most recent annual and quarterly reports filed with the Canadian securities regulators and available on the Company's profile on SEDAR at www.sedar.com, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on forward-looking statements. Except as required by law, Assure does not intend, and undertakes no obligation, to update any forward-looking statements to reflect, in particular, new information or future events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact

Scott Kozak, Investor and Media Relations
Assure Holdings Corp.
1-720-287-3093
Scott.Kozak@assureiom.com
